NAPLEX Quiz: Preparation And Routes

What this quiz covers

This quiz focuses on Preparation And Routes, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Prepare and spike the doxorubicin dose using a closed-system transfer device in a certified biological safety cabinet (correct answer)
2. Compound doxorubicin on an open countertop to avoid airflow disruption
3. Use non-sterile gloves because the final product is administered intravenously
4. Add doxorubicin to a glass of water for oral administration to reduce infusion reactions

Explanation: This question evaluates safe handling procedures for hazardous chemotherapy agents. The patient is receiving doxorubicin, an anthracycline chemotherapy requiring specialized preparation to protect healthcare workers from occupational exposure. Using a closed-system transfer device in a certified biological safety cabinet (A) is critical because it prevents aerosolization and environmental contamination while maintaining sterility during preparation. Compounding on an open countertop (B) exposes personnel to hazardous drug vapors and violates USP <800> standards. Using non-sterile gloves (C) is inadequate; chemotherapy preparation requires chemotherapy-rated gloves, often double-gloving, regardless of administration route. Oral administration in water (D) is incorrect as doxorubicin is only given intravenously and requires careful administration to prevent extravasation. The fundamental principle is that all hazardous drugs require engineering controls (safety cabinet), administrative controls (policies/procedures), and personal protective equipment to minimize occupational exposure during all handling steps.

Question 2

1. Measure each dose with an oral dosing syringe or dosing cup and administer immediately; do not mix the full day's dose into a large volume of beverage (correct answer)
2. Mix the entire day's doses into a 500 mL bottle of juice to improve adherence and administer throughout the day
3. Administer acetaminophen suspension via inhalation using a nebulizer for faster onset
4. Administer acetaminophen suspension sublingually and avoid swallowing for 10 minutes

Explanation: This question tests safe administration of oral suspensions in children, avoiding mixing errors. Key patient-specific factors include fever, gagging with syringes, and caregiver request to mix in juice. Measuring with dosing syringe and administering immediately without full-day mixing is appropriate to ensure accurate dosing and stability. Bulk mixing risks uneven distribution; inhalation or sublingual not indicated. A transferable clinical pearl is to dose liquids precisely and avoid dilution unless specified. For pediatrics, educate on tools to prevent errors.

Question 3

1. Switch to aspirin rectal suppository 300 mg once daily
2. Administer aspirin 81 mg enteric-coated tablet crushed via NG tube
3. Administer aspirin immediate-release (non–enteric-coated) tablet dispersed in water via NG tube (correct answer)
4. Switch to aspirin transdermal patch once daily

Explanation: This question tests alternative administration routes for antiplatelet therapy in patients with dysphagia, focusing on nasogastric tube compatibility. Key patient-specific factors include the patient's ischemic stroke, aspiration risk, NG tube placement, and need for secondary prevention with aspirin. Administering aspirin immediate-release (non–enteric-coated) tablet dispersed in water via NG tube is most appropriate as it allows absorption without enteric coating interference and maintains efficacy. Rectal suppository may have variable absorption; crushing enteric-coated tablets defeats the coating; transdermal aspirin is not available. A transferable clinical pearl is to select formulations compatible with enteral tubes, avoiding extended-release or enteric-coated products that cannot be crushed. For route selection, assess patient swallowing ability and formulation characteristics to ensure safe delivery.

Question 4

1. Use standardized warfarin tablet strengths and perform an independent double-check of dose against the most recent INR before dispensing (correct answer)
2. Automatically dispense a fixed warfarin dose of 10 mg by mouth daily for all patients to reduce variability
3. Store warfarin next to look-alike tablets (for example, metoprolol) to improve workflow efficiency
4. Instruct the patient to take extra doses if they eat leafy greens to compensate for vitamin K intake

Explanation: This question addresses error prevention strategies for warfarin, a high-alert anticoagulant with narrow therapeutic index. The patient is starting warfarin with appropriate bridging therapy, requiring careful dose management based on INR monitoring. Using standardized tablet strengths with independent double-checks against recent INR (A) is the most appropriate safety measure because it ensures dose accuracy and appropriateness before each dispensing, catching potential errors from INR misinterpretation or calculation mistakes. Dispensing a fixed 10 mg dose for all patients (B) is dangerous and ignores individual variability in warfarin response. Storing warfarin next to look-alike medications (C) increases selection errors through confirmation bias. Instructing patients to self-adjust doses based on diet (D) is inappropriate and dangerous; dietary consistency is preferred over dose adjustments. The key principle is that warfarin requires systematic safety checks at every step due to its complex dosing, narrow therapeutic window, and severe consequences of over- or under-anticoagulation.

Question 5

1. Administer potassium chloride as an IV push over 2 minutes for rapid correction
2. Dilute potassium chloride in an appropriate IV fluid and infuse using a controlled rate (pump) per institutional limits (correct answer)
3. Mix potassium chloride concentrate into the TPN bag at the bedside without verification to avoid delays
4. Store prepared potassium chloride admixtures at room temperature for 14 days regardless of diluent

Explanation: This question tests safe preparation of potassium chloride infusions to prevent cardiac complications. Key patient-specific factors include TPN use, hypokalemia, normal magnesium, and renal function. Diluting in IV fluid and infusing at controlled rates per limits is critical for safety. IV push is dangerous; bedside mixing risks errors; prolonged storage unstable. Critical steps include pump use and monitoring, pitfalls like rapid infusion. A transferable framework is to never push concentrated potassium and verify admixtures.

Question 6

1. Switch to transdermal fentanyl patch after assessing opioid tolerance and provide short-acting opioid for breakthrough pain (correct answer)
2. Switch to morphine extended-release tablets and crush them into applesauce
3. Switch to oral morphine solution and instruct the patient to inhale it via nebulizer
4. Discontinue opioids and use only acetaminophen to avoid swallowing issues

Explanation: This question tests alternative routes for opioid analgesia in patients with swallowing difficulties. Key patient-specific factors include metastatic cancer pain, mucositis, and insufficient oral morphine. Switching to transdermal fentanyl after assessing tolerance with breakthrough opioid is appropriate for continuous relief without oral intake. Crushing extended-release is unsafe; nebulized not indicated; discontinuation inadequate. A transferable clinical pearl is to use transdermal for stable chronic pain in dysphagic patients. For route selection, evaluate pain patterns and tolerance.

Question 7

1. Label the infusion with drug name, total dose, total volume, concentration, beyond-use time, and infusion duration (correct answer)
2. Add vancomycin to the total parenteral nutrition bag to reduce line access
3. Filter the infusion through a 0.22-micron filter only if precipitate is visible
4. Dilute vancomycin in sterile water only because saline causes drug degradation

Explanation: This question addresses critical preparation steps for intravenous medications, focusing on proper labeling to prevent medication errors. The patient's central line infection requires vancomycin therapy with appropriate safety measures. Comprehensive labeling with drug name, dose, volume, concentration, beyond-use time, and infusion duration (A) is the most critical step because it ensures all healthcare providers can verify the correct medication, dose, and administration parameters, preventing errors throughout the medication use process. Adding vancomycin to TPN (B) is contraindicated due to incompatibility and infection control concerns. Filtering through 0.22-micron filters only if precipitate is visible (C) is reactive rather than proactive; vancomycin doesn't require routine filtration. Diluting in sterile water only (D) is incorrect; vancomycin is compatible with normal saline, which is the standard diluent. The principle is that complete, accurate labeling is the foundation of IV medication safety, enabling verification at every step from preparation through administration.

Question 8

1. Use a valved holding chamber (spacer) with the metered-dose inhaler and have the child inhale slowly and deeply after actuation (correct answer)
2. Exhale into the inhaler mouthpiece before each puff to prime the device
3. Rinse mouth after albuterol to prevent oral candidiasis
4. Swallow the medication after actuation to improve systemic absorption

Explanation: This question evaluates proper inhaler technique counseling for a pediatric patient with coordination difficulties. The child's inability to coordinate actuation with inhalation is a common barrier to effective bronchodilator delivery in young patients. Using a valved holding chamber (spacer) with slow, deep inhalation after actuation (A) is essential because it eliminates the need for coordination, increases lung deposition from 10% to 20-30%, and reduces oropharyngeal deposition. Exhaling into the mouthpiece (B) is incorrect technique that could damage the device and reduce dose delivery. Mouth rinsing after albuterol (C) is unnecessary because albuterol doesn't cause oral candidiasis - this applies to inhaled corticosteroids. Swallowing medication after actuation (D) defeats the purpose of inhalation therapy and increases systemic side effects. The clinical pearl is that spacers are particularly valuable for children under 8 years old, elderly patients, and anyone with coordination difficulties, making inhaled therapy accessible and effective.

Question 9

1. Convert azithromycin to 500 mg by mouth once daily (correct answer)
2. Convert azithromycin to 250 mg by mouth once daily without a loading dose
3. Convert azithromycin to 500 mg intramuscularly once daily
4. Continue azithromycin intravenously because oral absorption is unreliable in all patients

Explanation: This question tests the appropriate conversion from intravenous to oral antibiotics in a clinically stable patient with community-acquired pneumonia. The key factors are clinical improvement (afebrile, hemodynamically stable), functioning GI tract, and ability to tolerate oral intake, which support IV-to-PO conversion. Converting azithromycin to 500 mg by mouth once daily (A) is correct because azithromycin has excellent oral bioavailability (37-40%) and the same daily dose is used for both IV and oral routes in pneumonia treatment. Option B (250 mg daily without loading) would provide subtherapeutic dosing for pneumonia. Intramuscular administration (C) is unnecessary when oral route is available and would cause patient discomfort. Continuing IV therapy (D) is inappropriate because azithromycin has reliable oral absorption in patients with functioning GI tracts. The principle of early IV-to-PO conversion reduces costs, IV complications, and facilitates earlier discharge while maintaining therapeutic efficacy in appropriate candidates.

Question 10

1. Switch to vancomycin 125 mg by mouth four times daily
2. Switch to linezolid 600 mg by mouth every 12 hours
3. Continue vancomycin intravenously at the current regimen (no oral substitution for bacteremia) (correct answer)
4. Switch to vancomycin 1,250 mg by mouth every 12 hours

Explanation: This question evaluates understanding of vancomycin's route-specific indications and the fundamental principle that oral vancomycin is not absorbed systemically. The patient has MRSA bacteremia requiring systemic therapy, with therapeutic vancomycin levels achieved intravenously. Continuing vancomycin intravenously (C) is the only appropriate option because oral vancomycin has negligible systemic bioavailability (<5%) and is only indicated for gastrointestinal infections like C. difficile colitis. Switching to oral vancomycin at any dose (A, D) would result in subtherapeutic systemic levels and treatment failure for bacteremia. Linezolid 600 mg orally (B), while having excellent oral bioavailability for MRSA, represents an unnecessary change when the patient is responding well to vancomycin with therapeutic levels. The clinical pearl is that vancomycin's oral formulation is exclusively for local GI effects, never for systemic infections, regardless of dose or patient preference for oral therapy.

Question 11

1. Switch to ciprofloxacin 500 mg orally every 12 hours (correct answer)
2. Switch to ciprofloxacin 250 mg orally once daily
3. Switch to ciprofloxacin ophthalmic drops 0.3% in each eye every 6 hours
4. Continue IV therapy until discharge because oral ciprofloxacin is not bioavailable

Explanation: This question tests IV-to-oral antibiotic step-down for pyelonephritis, considering bioavailability and dosing equivalence. Key patient-specific factors include clinical improvement, normal renal function, susceptibility to ciprofloxacin, and tolerance of oral intake. Switching to ciprofloxacin 500 mg orally every 12 hours is most appropriate due to its high oral bioavailability and equivalent dosing to IV for uncomplicated cases. Lower dosing is inadequate; ophthalmic drops are not systemic; continuing IV unnecessarily prolongs hospitalization. A transferable clinical pearl is that ciprofloxacin has near 100% oral bioavailability, allowing 1:1 IV-to-oral conversion. For step-down decisions, evaluate stability and use agents with excellent absorption to facilitate discharge.

Question 12

1. Switch to sumatriptan subcutaneous injection (correct answer)
2. Continue sumatriptan tablet and advise taking with a full meal to prevent vomiting
3. Switch to sumatriptan extended-release oral capsule and open it into water
4. Switch to sumatriptan topical cream applied to the temples

Explanation: This question tests non-oral administration routes for migraine relief in patients with severe nausea and vomiting. Key patient-specific factors include inability to tolerate oral sumatriptan, negative pregnancy test, and sulfonamide allergy (not contraindicating sumatriptan). Switching to sumatriptan subcutaneous injection is most appropriate for rapid onset and bypassing gastrointestinal issues. Advising oral with meals may worsen vomiting; extended-release cannot be opened; topical cream is not available. A transferable clinical pearl is that subcutaneous triptans provide the fastest relief for migraines with emesis. For route selection, consider barriers like nausea and choose formulations with quick absorption.

Question 13

1. Increase the infusion rate to complete the dose in 30 minutes to reduce time exposed
2. Ensure the dose is diluted appropriately and infused slowly (generally at least 60 minutes, longer for larger doses) to reduce infusion-related reactions (correct answer)
3. Administer vancomycin intramuscularly to avoid infusion reactions
4. Store the prepared vancomycin infusion at room temperature for 7 days regardless of diluent

Explanation: This question tests preparation and administration steps for vancomycin to prevent infusion-related reactions. Key patient-specific factors include MRSA cellulitis, therapeutic trough, and reported flushing/itching. Ensuring appropriate dilution and slow infusion (at least 60 minutes, longer for larger doses) is critical to reduce reactions like red man syndrome. Increasing rate worsens reactions; intramuscular is not indicated; prolonged storage reduces stability. Critical steps include rate calculation and monitoring, with pitfalls like rapid infusion. A transferable framework is to infuse vancomycin slowly and premedicate if needed for reaction-prone patients.

Question 14

1. Crush metoprolol succinate extended-release tablet and administer via feeding tube
2. Switch to metoprolol tartrate immediate-release tablets that can be crushed and administered via feeding tube with appropriate dosing frequency (correct answer)
3. Switch to metoprolol succinate and administer sublingually for faster onset
4. Discontinue beta-blocker therapy because alternative routes are not available

Explanation: This question tests administration routes for beta-blockers in patients with swallowing impairment, focusing on crushable formulations. Key patient-specific factors include atrial fibrillation, delirium, elevated heart rate, and feeding tube use. Switching to metoprolol tartrate immediate-release tablets that can be crushed and administered via feeding tube with appropriate dosing is best for continued rate control. Crushing extended-release alters pharmacokinetics; sublingual or discontinuation is inappropriate. A transferable clinical pearl is to use immediate-release forms for enteral tube administration when extended-release cannot be crushed. For route changes, evaluate formulation compatibility and adjust frequency accordingly.

Question 15

1. Swallow the tiotropium capsule whole with water to ensure full absorption
2. Pierce the capsule in the HandiHaler and inhale the powder; do not swallow the capsule (correct answer)
3. Use the device only during acute shortness of breath for quick relief
4. Rinse the capsule under water before inserting it to reduce throat irritation

Explanation: This question tests counseling for dry powder inhalers like tiotropium HandiHaler, emphasizing proper technique. Key patient-specific factors include COPD diagnosis, reduced FEV1, and daily maintenance use. Piercing the capsule in the HandiHaler and inhaling the powder without swallowing is essential for correct delivery to the lungs. Swallowing provides no benefit; using only as needed defeats maintenance purpose; rinsing capsules alters integrity. A transferable clinical pearl is that inhalation capsules must never be ingested to avoid systemic inefficacy. For device counseling, demonstrate technique and confirm understanding to optimize therapy.

Question 16

1. Store at room temperature (25°C) indefinitely and protect from light by keeping it on the kitchen counter
2. Store in the refrigerator (2°C to 8°C) in the original carton; do not freeze; if kept at room temperature, follow product-specific time limits (correct answer)
3. Store in the freezer (-20°C) and thaw in hot water immediately before injection
4. Store in a weekly pill organizer to reduce packaging waste and improve adherence

Explanation: This question tests proper storage conditions for biologic medications like adalimumab to maintain stability and efficacy. Key patient-specific factors include the patient's rheumatoid arthritis, concomitant methotrexate use, negative TB and hepatitis screens, and the subcutaneous pen formulation. Storing in the refrigerator (2°C to 8°C) in the original carton, not freezing, and following product-specific room temperature limits is correct to prevent degradation and ensure potency. Room temperature indefinitely or in a pill organizer risks instability; freezing and thawing can denature the protein; direct sunlight exposure is harmful. A transferable clinical pearl is that most biologics require refrigeration to preserve their protein structure, with excursions allowed per labeling. For storage decisions, consult product inserts and educate patients on handling to avoid waste and maintain therapeutic effectiveness.

Question 17

1. Rinse the mouth and spit after using the budesonide/formoterol inhaler to reduce risk of oral candidiasis (correct answer)
2. Shake the inhaler, exhale into the mouthpiece, then inhale quickly and stop breathing immediately
3. Store the inhaler in the freezer between uses to preserve dose consistency
4. Use the controller inhaler only when symptoms occur to minimize steroid exposure

Explanation: This question tests essential counseling for inhaled corticosteroids in asthma management, focusing on techniques to minimize adverse effects. Key patient-specific factors include the patient's moderate persistent asthma, current regimen with budesonide/formoterol and albuterol, and reduced peak flow indicating suboptimal control. Rinsing the mouth and spitting after using the budesonide/formoterol inhaler is essential to reduce the risk of oral candidiasis, a common side effect of inhaled corticosteroids. Incorrect techniques like exhaling into the mouthpiece or storing in the freezer can compromise dose delivery and drug stability; using only when symptomatic defeats the controller purpose. A transferable clinical pearl is that proper inhaler technique and post-use rinsing are key to maximizing benefits and minimizing local adverse effects in asthma therapy. For inhalation routes, always provide device-specific education and monitor for adherence to improve outcomes.

Question 18

1. Switch to levetiracetam 1,000 mg orally every 12 hours (correct answer)
2. Switch to levetiracetam 250 mg orally once daily
3. Switch to levetiracetam ophthalmic solution administered orally
4. Continue IV therapy because levetiracetam is not absorbed orally

Explanation: This question tests IV-to-oral transition for antiepileptics, considering bioavailability. Key patient-specific factors include resolved status epilepticus, ability to swallow, and normal renal function. Switching to levetiracetam 1,000 mg orally every 12 hours matches IV dosing due to high bioavailability. Lower dose inadequate; ophthalmic not oral; continuing IV unnecessary. A transferable clinical pearl is levetiracetam's 100% oral absorption allows 1:1 conversion. For transitions, assess stability and use equivalent doses.

Question 19

1. Switch to carbidopa/levodopa orally disintegrating tablets (ODT) if appropriate and administer on the tongue (correct answer)
2. Switch to carbidopa/levodopa extended-release tablets and crush them into pudding
3. Administer carbidopa/levodopa tablets rectally for equivalent absorption
4. Open carbidopa/levodopa capsules and sprinkle contents into hot soup to improve dissolution

Explanation: This question tests administration routes for Parkinson medications in dysphagic patients. Key patient-specific factors include difficulty swallowing, drooling, and refusal of crushed tablets. Switching to carbidopa/levodopa orally disintegrating tablets administered on the tongue is appropriate for ease without swallowing. Crushing extended-release unsafe; rectal or sprinkling in soup not indicated. A transferable clinical pearl is ODTs bypass swallowing issues while maintaining efficacy. For route changes, prioritize patient preferences and formulation options.

Question 20

1. Switch ceftriaxone to cefpodoxime 200 mg orally twice daily
2. Switch ceftriaxone to levofloxacin 750 mg orally once daily (correct answer)
3. Continue ceftriaxone IV and discontinue azithromycin
4. Switch azithromycin IV to azithromycin 250 mg orally once daily and stop ceftriaxone

Explanation: This question tests the concept of transitioning from intravenous to oral antibiotics for community-acquired pneumonia, focusing on appropriate step-down therapy in the context of drug allergies and clinical stability. Key patient-specific factors include the documented anaphylaxis to penicillin, current IV regimen of ceftriaxone and azithromycin, clinical improvement with afebrile status, normal renal function, and the goal of discharge within 24 hours. Switching ceftriaxone to levofloxacin 750 mg orally once daily is the best choice as it provides monotherapy with a respiratory fluoroquinolone that covers both typical and atypical pathogens, avoids beta-lactam cross-reactivity risks, and has excellent oral bioavailability for seamless transition. Switching to cefpodoxime is suboptimal due to potential cross-reactivity with penicillin allergy and the need for combination therapy to cover atypicals, while continuing IV ceftriaxone contradicts the oral transition goal, and switching only azithromycin to oral while stopping ceftriaxone provides inadequate coverage for gram-negative pathogens. A transferable clinical pearl is that patients with severe beta-lactam allergies should preferentially receive respiratory fluoroquinolones for CAP step-down, ensuring equivalent dosing and bioavailability. When deciding on IV-to-oral switches, always assess clinical stability, oral tolerance, and pathogen susceptibility to optimize therapy and reduce hospital stay.